drug: sertraline

• Clinical class: antidepressant
• Action: Selective serotonin reuptake inhibitor
• CSA schedule: none
• DEA number: none
• FDA Medwatch Consumer Advisory (interaction with pimozide)
• MEDLINEplus^® Drug Information

U.S. Preparations:

• Zoloft^® (Pfizer) FDA approved:
  12.30.1991 for treatment of depression
  7.8.1997 Obsessive Compulsive Disorder, Panic Disorder
  12.7.99 Posttraumatic Stress Disorder
  8.16.2001 long term treatment of Posttraumatic Stress Disorder
  10.12.2001 pediatric obsessive compulsive disorder
  5.16.2002 premenstrual dysphoric disorder (PMDD)
  2.7.2003 Social Anxiety Disorder
  U.S. Prescribing Information
• Zoloft^® concentrate (Pfizer) FDA approved:
  12.7.99, depression, Obsessive Compulsive Disorder, Panic Disorder
  10.12.2001 pediatric obsessive compulsive disorder
  2.7.2003 Social Anxiety Disorder
  U.S. Prescribing Information

Preparations Outside U.S.:

• Aremis, Besitran, Gladem, Lustral^®, Serad, Serlain, Tatig, Tresleen 

Stephen Stahl's Clinical Pearls* (Consult your physician before making any change in your treatment.)

• Weak 2D6 inhibitor.
• More diarrhea.
• FDA label of depression and OCD.
• Often activating and panicogenic in panic disorder.
• Least selective over dopamine.
• Consider for atypical depression.
• Consider avoiding in patients with multiple GI somatic symptoms, agitation and/or insomnia who wish to avoid sexual dysfunction.

*Reprinted with permission from: Stahl, Stephen M Psychopharmacology of Antidepressants Paperback 1997 Martin Dunitz, Ltd & Blackwell Science You cannot fully appreciate this book until you have seen the extraordinary illustrations of every aspect of this area of psychopharmacology and neurochemistry. Loaded with practical clinical "pearls."

http://www.behavenet.com/capsules
Search Capsules™ | Terms of Use | Request New Term
Capsules™ Copyright © 1997-2009 BehaveNet®